ACGX Stock Chart - 1 Month
ACGX Stock Chart - 3 Month
ACGX Stock Chart - 6 Month
ACGX Stock Chart - 1 Year
ACGX Stock Chart - 2 Year
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...
Continue Reading
Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...
Continue Reading
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...
Continue Reading
Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...
Continue Reading
Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...
Continue Reading
Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...
Continue Reading
Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...
Continue Reading